NORDFERTIL Research Lab Stockholm

Our main research areas
• Strategies to mature pluripotent stem and immature germ cells into mature gametes
• Gonadotoxic late effects in paediatric haematology and oncology
• Hormonal effects in the male and female reproductive tract
• Establishment of in vitro gonadal toxicology tests


Survival rates among childhood cancer patients have progressively increased over the past four decades, in particular as a result of the development of more effective cancer treatments. Three out of four children will be cured of their disease. However, success has come at a cost and some patients will suffer from adverse effects later on. One of these late effects may be treatment-induced infertility. Boys who have matured into puberty are offered sperm preservation before treatment starts. However, for boys before puberty there is as yet no procedure that may preserve fertility. Most childhood cancer treatments will have only a minor impact on future fertility, while some treatments are known to be very harmful as regards reproductive function. So far, boys facing such treatments have almost no chance to father their own biological children later in life.

To address the concerns of many patients and parents and to open a forum concentrating on infertility as a disease, or a treatment-related late effect in childhood cancer survivors, the “Nordic Network for Gonadal Preservation after Cancer Treatment in Children and Young Adults” was initiated in 2008 and resulted in recommendations concerning fertility preservation for girls/boys and young women/men with childhood cancer. Up to now, advances in females have been made, but a similar development is still missing for young boys. Therefore, the idea of establishing a scientific network in order to intensify and combine research efforts on fertility preservation for young boys was born. The network is named NORDFERTIL

The research of this network is centralized at the NORDFERTIL Research Lab Stockholm at Karolinska Institutet and includes research areas including pluripotent stem cell cultures as well as the development of novel in vitro systems for male gonadal cell development and differentiation.

In addition to the research performed, NORDFERTIL will focus on the establishment of protocols for clinical applications. Therefore, the results obtained by evaluation of testicular biopsy material and cell culture experiments will be used to generate and/or optimize already existing protocols for clinical use in cooperation with all units included in NORDFERTIL.

The following questions will be addressed:

  1. Which are the best cryopreservation protocols as regards later differentiation of early male germ cells in vitro?
  2. Which are the best strategies to monitor cancer cell contamination in vitro?
  3. Which are the best strategies and culture conditions for human spermatogenesis in vitro?
  4. Which clinical efficacy and safety measures should be monitored?